NEW YORK STOCK EXCHANGE, INC. · GKOS
+2.73% · +$4.40 · Vol 1.2M
Market closed · last close 4:00 PM ET · price as of 19:00:00 ET
Glaukos Corp

Glaukos Corp

Health Care
$165.69
Card
Relationship Map

Follow $GKOS

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $GKOS by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
GKOS
Glaukos Corp
Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

64/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: MEDIUM · 6 of 6 factors measured · Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GKOS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GKOS catalysts
About Glaukos Corp
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed since
2015
Employees
1K
Country
US

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$160.06
Day high
$166.97
Day low
$159.89
Previous close
$161.29
52W high
$189.55
-12.59% from high
52W low
$74.67
79% of range
Market cap
$9.5B
EPS
$-3.2602
Beta
0.17
Shares out
59M
Volume
1.2M
1.31× rel vol
Avg volume
911K
VWAP
$164.23
Price history computed in-house
1W
+1.18%
1M
-2.75%
3M
+8.49%
1Y
+100.69%
YTD
+46.75%
SMA 50 $172.75 · below
SMA 200 $136.29 · above
52W position 79%

GKOS overview

Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file
Loading financial statements
Loading GKOS Form 4 filings
Public disclosures

Congress activity in GKOS

No receipt-qualified filings found.

Federal contracts

GKOS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GKOS in this window.
Lobbying spend

GKOS lobbying filings, year to date.

Registered lobbying filings matched to Glaukos Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GKOS in this window.
Loading news for GKOS
Analyst ratings
Sovereign unlock shows live analyst consensus for GKOS.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.